Moleculin Biotech, Inc. (MBRX)
| Market Cap | 6.57M -70.3% |
| Revenue (ttm) | n/a |
| Net Income | -8.66M |
| EPS | -42.13 |
| Shares Out | 973.87K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,898 |
| Open | 6.75 |
| Previous Close | 6.83 |
| Day's Range | 6.66 - 6.75 |
| 52-Week Range | 3.23 - 227.05 |
| Beta | 2.09 |
| Analysts | Strong Buy |
| Price Target | 240.00 (+3,458.19%) |
| Earnings Date | Nov 16, 2026 |
About MBRX
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for MBRX stock is "Strong Buy." The 12-month stock price target is $240.0, which is an increase of 3,458.19% from the latest price.
News
Moleculin Strengthens Global Intellectual Property Portfolio Around Annamycin, Secures Korean Patent Allowance
Patent protection spans North America, Europe & Asia-Pacific Rim Korean decision to grant extends reconstitution protection into another key Asia-Pacific market, reinforcing a multi-layered portfolio ...
Moleculin Biotech Reports Third Quarter 2026 Financial Results as Pivotal MIRACLE Trial Advances Toward Key Q1 2027 Data Readout
- Completed treatment of all 90 patients in Part A of the pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in relapsed or refractory acute myeloid leukemia (AML)
Moleculin Biotech Quarterly report: Q3 2026
Moleculin Biotech has published its Q3 2026 quarterly earnings report on November 13, 2026.
Moleculin Biotech Earnings release: Q3 2026
Moleculin Biotech released its Q3 2026 earnings on November 13, 2026, summarizing the period's financial results.
Moleculin granted Australian patent covering preliposomal Annamycin lyophilizate
Moleculin Biotech (MBRX) announced the grant of an Australian patent covering the preparation of preliposomal Annamycin lyophilizate. Australian Patent No. 2020303572 was granted to Moleculin and The ...
Moleculin Secures Australian Patent for Annamycin Formulation Technology
Patent strengthens intellectual property protection for preparation of preliposomal Annamycin lyophilizate
Moleculin Biotech announces new preclinical data on Annamycin combo
Moleculin Biotech (MBRX) announced new preclinical data showing that its lead drug candidate, Annamycin, combined with PD-1 immune checkpoint blockade, extended survival in pancreatic cancer models be...
Preclinical Data Show Annamycin Makes Pancreatic Cancer Responsive to Checkpoint Inhibitors, Opening a Combination Path with Immunotherapies
Inhibition of CD8+ T cells shortens survival in Annamycin-treated mice, demonstrating the immune system is a functional contributor to Annamycin's antitumor activity, not a bystander
Moleculin Biotech to present annamycin data at ASH meeting
Moleculin Biotech (MBRX) announced that an abstract highlighting data from its lead drug candidate, Annamycin, has been accepted for presentation at the 2026 American Society of Hematology Annual Meet...
Moleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting
First interim results from pivotal Phase 2/3 trial highlight encouraging remission rates in patients with relapsed or refractory AML
Moleculin Biotech completes dosing in Part A of MIRACLE trial
Moleculin Biotech (MBRX) announced that dosing has been completed in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine for the treatment of adults…
Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027
Milestone underscores execution of pivotal Phase 2/3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia (AML)
Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial
Access the Moleculin CEO Corner here
Moleculin Biotech trading halted, news pending
19:50 EDT Moleculin Biotech (MBRX) trading halted, news pending
Moleculin Biotech announces 1-for-20 reverse stock split
Moleculin Biotech (MBRX) announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a…
Moleculin Announces Reverse Stock Split
HOUSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it filed an amendment to its amended and restated certificate of...
Moleculin Biotech Slides: Corporate presentation
Moleculin Biotech has posted slides in relation to its latest quarterly earnings report, which was published on October 16, 2026.
Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit
HOUSTON, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that it will present at the upcoming 2026 Maxim Growth Summit in New Yo...
Moleculin Biotech completes enrollment in Part A of Phase 2/3 R/R MIRACLE trial
Moleculin Biotech (MBRX) announced that it has completed and closed enrollment in Part A of its Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine for the treatment of…
Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout
HOUSTON, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that it has completed and closed enrollment in Part A of its pivotal P...
Moleculin Biotech announces publication of analysis of Annamycin in Frontiers
Moleculin Biotech (MBRX) announced the publication of a peer-reviewed analysis of the cardiac safety of Annamycin in Frontiers in Cardiovascular Medicine. The publication, titled “Cardiac safety of L-...
Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine
– Pooled analysis of five clinical trials found no clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding traditional anthracycline limits
Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR
Data presented at the AACR Conference on Pancreatic Cancer indicate Annamycin's antitumor activity is partially mediated by CD8+ T cells, supporting a potential immune-mediated mechanism alongside its...
Moleculin Biotech secures Mexican patent protecting Annamycin through 2040
Moleculin Biotech (MBRX) announced that the Mexican Patent Office has granted Patent No. 436849, further strengthening the Company’s global intellectual property portfolio protecting its proprietary l...
Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040
Strengthens Global Intellectual Property Estate for Annamycin's Proprietary Liposomal Formulation Designed to Target Lung Metastases While Supporting Long-Term Commercial Opportunity